Long-Term Neuropathy Common in Breast Cancer After Chemotherapy

Why It Matters

Persistent chemotherapy‑induced neuropathy threatens quality of life for older breast‑cancer survivors and may increase healthcare utilization, highlighting the need for treatment selection and survivorship care strategies.

Key Takeaways

• Chemotherapy raises long-term neuropathy risk to >60% in seniors
• Taxane users have three times odds of neuropathy vs non‑chemo
• Paclitaxel causes higher neuropathy rates than docetaxel
• Neuropathy linked to balance issues but not increased falls
• Black survivors face higher neuropathy odds than white peers

Pulse Analysis

The latest findings from Jackson et al. underscore that chemotherapy‑induced peripheral neuropathy (CIPN) is not merely an acute side effect but a chronic condition affecting a majority of older breast‑cancer survivors. Over 60 % of patients who underwent chemotherapy reported moderate to severe neuropathy five years post‑treatment, a stark rise from the 36 % baseline in non‑chemo cohorts. With more than four million breast‑cancer survivors in the United States, this translates into hundreds of thousands living with persistent sensory deficits, pain, and reduced mobility that can erode functional independence.

The study isolates taxane chemotherapy as the primary driver, revealing a three‑fold increase in neuropathy odds compared with non‑taxane regimens. Notably, paclitaxel patients experienced neuropathy at a 73 % rate versus 56 % for docetaxel, suggesting that drug selection can materially alter long‑term outcomes. Racial disparities also surfaced, with Black survivors facing an 80 % higher likelihood of neuropathy than white peers. These data compel oncologists to weigh neurotoxicity risk alongside efficacy, especially for older adults, and to consider docetaxel or alternative agents when neuropathy risk is paramount.

Given that neuropathy was linked to balance problems but not to an uptick in falls, clinicians have a missed opportunity to intervene with fall‑prevention programs and targeted rehabilitation. The authors call for systematic survivorship monitoring, patient‑reported outcome tools, and research into pharmacologic or physical therapies that could mitigate nerve damage. Health systems should integrate neuropathy screening into routine follow‑up visits, and payers may need to cover supportive services to curb downstream costs. Ultimately, proactive management could preserve quality of life for millions of aging cancer survivors.